Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$68 Mln
P/E Ratio
--
P/B Ratio
5.8
Industry P/E
--
Debt to Equity
1.16
ROE
-1.2 %
ROCE
-63.18 %
Div. Yield
0 %
Book Value
0.2
EPS
-0.38
CFO
$-125.97 Mln
EBITDA
$-160.18 Mln
Net Profit
$-168.05 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cytosorbents Crp (CTSO)
| 17.93 | 9.12 | 5.22 | 32.49 | -25.25 | -34.41 | -17.25 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cytosorbents Crp (CTSO)
| -17.89 | -28.39 | -63.01 | -47.43 | 107.01 | -52.35 | 24.16 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.65 | 10,289.47 | 14.38 | 12.69 | |
| 72.28 | 9,544.04 | 92.52 | 2.52 | |
| 158.95 | 8,064.21 | -- | -25.23 | |
| 278.44 | 10,728.90 | 773.26 | 1.2 |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany,... and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. Address: 305 College Road East, Princeton, NJ, United States, 08540 Read more
CEO & Director
Dr. Phillip P. Chan M.D., Ph.D.
CEO & Director
Dr. Phillip P. Chan M.D., Ph.D.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cytosorbents Crp (CTSO) stood at $ 47 Mln as on 31-Dec-24
The share price of Cytosorbents Crp (CTSO) is $1.07 (NASDAQ) as of 23-Apr-2025 13:47 EDT. Cytosorbents Crp (CTSO) has given a return of -25.25% in the last 3 years.
Cytosorbents Crp (CTSO) has a market capitalisation of $ 68 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cytosorbents Crp (CTSO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cytosorbents Crp (CTSO) and enter the required number of quantities and click on buy to purchase the shares of Cytosorbents Crp (CTSO).
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. Address: 305 College Road East, Princeton, NJ, United States, 08540
The CEO & director of Dr. Phillip P. Chan M.D., Ph.D.. is Cytosorbents Crp (CTSO), and CFO & Sr. VP is Dr. Phillip P. Chan M.D., Ph.D..
There is no promoter pledging in Cytosorbents Crp (CTSO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Cytosorbents Crp (CTSO) | Ratios |
|---|---|
|
Return on equity(%)
|
-120.52
|
|
Operating margin(%)
|
-83.62
|
|
Net Margin(%)
|
-82.46
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cytosorbents Crp (CTSO) was $0 Mln.
$-0.03
(
